1. Home
  2. EYPT vs CEPO Comparison

EYPT vs CEPO Comparison

Compare EYPT & CEPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • CEPO
  • Stock Information
  • Founded
  • EYPT 1987
  • CEPO 2020
  • Country
  • EYPT United States
  • CEPO United States
  • Employees
  • EYPT N/A
  • CEPO N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • CEPO
  • Sector
  • EYPT Industrials
  • CEPO
  • Exchange
  • EYPT Nasdaq
  • CEPO NYSE
  • Market Cap
  • EYPT 484.4M
  • CEPO 315.4M
  • IPO Year
  • EYPT 2005
  • CEPO 2025
  • Fundamental
  • Price
  • EYPT $8.25
  • CEPO $12.16
  • Analyst Decision
  • EYPT Strong Buy
  • CEPO
  • Analyst Count
  • EYPT 8
  • CEPO 0
  • Target Price
  • EYPT $24.29
  • CEPO N/A
  • AVG Volume (30 Days)
  • EYPT 895.1K
  • CEPO 421.6K
  • Earning Date
  • EYPT 05-07-2025
  • CEPO 01-01-0001
  • Dividend Yield
  • EYPT N/A
  • CEPO N/A
  • EPS Growth
  • EYPT N/A
  • CEPO N/A
  • EPS
  • EYPT N/A
  • CEPO 0.10
  • Revenue
  • EYPT $56,042,000.00
  • CEPO N/A
  • Revenue This Year
  • EYPT N/A
  • CEPO N/A
  • Revenue Next Year
  • EYPT N/A
  • CEPO N/A
  • P/E Ratio
  • EYPT N/A
  • CEPO $128.86
  • Revenue Growth
  • EYPT 12.04
  • CEPO N/A
  • 52 Week Low
  • EYPT $3.91
  • CEPO $10.04
  • 52 Week High
  • EYPT $13.99
  • CEPO $13.00
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 72.87
  • CEPO N/A
  • Support Level
  • EYPT $5.46
  • CEPO N/A
  • Resistance Level
  • EYPT $8.36
  • CEPO N/A
  • Average True Range (ATR)
  • EYPT 0.57
  • CEPO 0.00
  • MACD
  • EYPT 0.24
  • CEPO 0.00
  • Stochastic Oscillator
  • EYPT 96.21
  • CEPO 0.00

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About CEPO CANTOR EQUITY PARTNERS I INC

Cantor Equity Partners I Inc is a blank check company.

Share on Social Networks: